Skip to content

    Research Use Only

    This site is an educational resource for research compounds. We do not endorse human consumption of any compound. We rank every vendor on the same public methodology, and we earn a commission on purchases through some of our links. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    Compare notes with other researchers. Join r/BodyHackGuide

    KW-6356

    NootropicsPhase 2b (program discontinued)

    Also known as: KW6356

    KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Adenosine A2A receptors are concentrated in the basal ganglia, where they oppose dopamine signaling, so blocking them is a non-dopaminergic way to support motor function.

    Route: OralMW: 397.4CAS: 858979-50-7
    Last reviewed:
    Nootropics
    Category
    Phase 2b (program discontinued)
    Research Stage

    Overview

    Lowest Price per mg

    BHG Labs logo

    BHG Labs

    $109.99

    1 bottle · capsule

    Coupon:BHG20

    At A Glance

    Mechanism

    KW-6356 binds adenosine A2A receptors as a high-affinity antagonist and inverse agonist, reducing both adenosine-stimulated and constitutive A2A signaling in striatal output pathways. By relieving A2A-mediated inhibition of dopaminergic motor circuits it improves motor output wit…

    Routes
    Oral
    Potential Benefits
    Selective adenosine A2A antagonism / inverse agonismStudied for motor symptoms in Parkinson's disease (Phase 2a monotherapy + Phase 2b adjunct)Non-dopaminergic mechanismResearched for the wakefulness / anti-fatigue effects of A2A blockade

    Overview

    KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Adenosine A2A receptors are concentrated in the basal ganglia, where they oppose dopamine signaling, so blocking them is a non-dopaminergic way to support motor function. It is a structurally distinct successor to istradefylline (Nourianz).

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    858979-50-7

    Molecular Formula

    Not yet available

    Molecular Mass

    397.4 g/mol

    Dosing & Protocols

    Unlock Dosing Protocols

    Free account gets you:

    • View beginner, intermediate & advanced protocols
    • See weight-based dosing calculations
    • Access cycle length & frequency data

    Join other researchers already signed up

    Research

    Unlock Research Data

    Free account gets you:

    • Browse PubMed study summaries
    • See clinical trial phases & results
    • Access mechanism of action details

    Join other researchers already signed up

    Interactions

    Contraindications

    Investigational compound with no clinical-use guidance. Avoid in pregnancy/breastfeeding.

    Research Disclaimer

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Best Price

    $109.99

    Best $/mg

    —

    Vendors

    1

    Listings

    1

    capsule

    Form
    Sort
    Vendor Product Form Qty Price $/mg Coupon
    BHG Labs logo
    BHG Labs
    70
    🇺🇸US
    KW-6356 capsule 1 bottle● In Stock $109.99BEST —

    Get KW-6356 Price Drop Alerts

    Set a target price and we'll notify you when any vendor drops below it. Current lowest: $109.99

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with KW-6356.

    Current low
    $109.99
    as of Jul 1, 2026
    7-day low
    —
    no 7d data yet
    30-day low
    —
    no 30d data yet
    30-day change
    —
    baseline building

    Tracking since Jul 1, 2026 · 1 data point

    Vendors Selling KW-6356

    How we score these vendors

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

    View Scorecard

    Related Compounds

    View All

    9-Me-BC (9-Methyl-β-carboline)

    NootropicsPreclinical

    9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].

    t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists.
    6 PubMedView Profile

    Aniracetam

    NootropicsApproved (Italy)

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    PreclinicalView Profile

    Bemethyl (bemitil)

    NootropicsApproved (Russia)

    Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.

    t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
    PreclinicalView Profile

    Bromantane

    NootropicsRussia Approved

    Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

    34 PubMedView Profile

    Cyclazodone

    NootropicsPreclinical

    Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.

    PreclinicalView Profile

    Dihexa

    NootropicsPreclinical

    Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

    t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
    1 PubMedView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for KW-6356

    Lowest Price per mg

    BHG Labs logo

    BHG Labs

    $109.99

    1 vendors · 1 listings

    Research Score

    30

    0 PubMed results

    Quality Indicators

    Data Completeness

    63%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Results
    Interactions
    Vendor Listings

    Quick Facts

    Molecular Weight

    397.4 g/mol

    Administration

    Oral

    CAS Number

    858979-50-7

    Trial Phase

    Phase 2b (program discontinued)

    0

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    What is KW-6356 used for in research?

    KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Adenosine A2A receptors are concentrated in the basal ganglia, where they oppose dopamine signaling, so blocking them is a non-dopaminergic way to support motor function. It is a structurally distinct successor to istradefylline (Nourianz).

    What forms does KW-6356 come in?

    KW-6356 is available in capsule form.

    How much does KW-6356 cost?

    Prices start at $109.99 across 1 vendor.

    How do I compare KW-6356 vendors?

    Compare prices, payment methods, shipping, and COA scores across 1 vendor.

    Research Tools

    Related Compounds

    View All

    9-Me-BC (9-Methyl-β-carboline)

    NootropicsPreclinical

    9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].

    t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists.
    6 PubMedView Profile

    Aniracetam

    NootropicsApproved (Italy)

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    PreclinicalView Profile

    Bemethyl (bemitil)

    NootropicsApproved (Russia)

    Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.

    t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
    PreclinicalView Profile

    Bromantane

    NootropicsRussia Approved

    Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

    34 PubMedView Profile

    Cyclazodone

    NootropicsPreclinical

    Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.

    PreclinicalView Profile

    Dihexa

    NootropicsPreclinical

    Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

    t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
    1 PubMedView Profile

    Research Benches

    Reference pages that put KW-6356 next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Free 2026 Peptide Cheat Sheet (PDF)

    Reconstitution math, concentration charts, half-lives, and vendor links. The reference we wish we had on day one.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.